Ad is loading...
HGXRX
Price
$15.33
Change
-$0.14 (-0.90%)
Updated
Nov 15 closing price
RSLEX
Price
$68.12
Change
-$0.84 (-1.22%)
Updated
Nov 15 closing price
Ad is loading...

HGXRX vs RSLEX

Header iconHGXRX vs RSLEX Comparison
Open Charts HGXRX vs RSLEXBanner chart's image
Hartford Global Impact R3
Price$15.33
Change-$0.14 (-0.90%)
VolumeN/A
CapitalizationN/A
American Funds SMALLCAP World R4
Price$68.12
Change-$0.84 (-1.22%)
VolumeN/A
CapitalizationN/A
HGXRX vs RSLEX Comparison Chart
Loading...
View a ticker or compare two or three
VS
HGXRX vs. RSLEX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HGXRX is a StrongBuy and RSLEX is a Buy.

FUNDAMENTALS
Fundamentals
RSLEX has more cash in the bank: 74.7B vs. HGXRX (240M). RSLEX pays higher dividends than HGXRX: RSLEX (0.65) vs HGXRX (0.44). HGXRX was incepted earlier than RSLEX: HGXRX (8 years) vs RSLEX (22 years). HGXRX is a more actively managed with annual turnover of: 34.00 vs. RSLEX (29.00). HGXRX has a lower initial minimum investment than RSLEX: HGXRX (0) vs RSLEX (250). HGXRX annual gain was more profitable for investors over the last year : 19.85 vs. RSLEX (16.00). HGXRX return over 5 years is better than : 37.83 vs. RSLEX (18.89).
HGXRXRSLEXHGXRX / RSLEX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence8 years22 years-
Gain YTD8.8783.747237%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets240M74.7B0%
Annual Yield % from dividends0.440.6568%
Returns for 1 year19.8516.00124%
Returns for 3 years-11.06-25.8643%
Returns for 5 years37.8318.89200%
Returns for 10 yearsN/A39.00-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VIPS13.93-0.03
-0.21%
Vipshop Holdings Limited
LIN449.10-4.39
-0.97%
Linde plc
TLRY1.35-0.03
-2.17%
Tilray Brands
ZVRA8.62-0.41
-4.54%
Zevra Therapeutics
ELUT3.56-0.27
-7.05%
Elutia